Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 93 |
| Active Pipeline (Recruiting Now) | 56 (29) |
| Completed vs Stopped Early | 17 / 20 (21.5%) |
| Median Closed Actual Enrollment | 23 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Dana-Farber Cancer Institute | Boston, MA | 85 |
| Brigham and Women's Hospital | Boston, MA | 26 |
| Beth Israel Deaconess Medical Center | Boston, MA | 25 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT04893109 | ATEMPT 2.0: Adjuvant T-DM1 vs TH | Phase II | RECRUITING |
| NCT04620187 | Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas | Phase II | RECRUITING |
| NCT04468061 | Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC | Phase II | RECRUITING |
| NCT03587740 | ATOP TRIAL: T-DM1 in HER2 Positive Breast Cancer | Phase II | ACTIVE NOT RECRUITING |
| NCT04569747 | A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-p | Phase II | ACTIVE NOT RECRUITING |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Dana-Farber Cancer Institute across sibling Meru public-data platforms.
Explore interactive annual charts and M&A subsidiary rollups in the Dana-Farber Cancer Institute Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.